Rheumatology International

, Volume 27, Issue 3, pp 269–274

Immunogenicity, efficacy and adverse events of adalimumab in RA patients

  • Niko K. Bender
  • Christoph E. Heilig
  • Benjamin Dröll
  • Jessica Wohlgemuth
  • Franz-Paul Armbruster
  • Bernhard Heilig
Original Article

Abstract

To assess the immunogenicity of adalimumab, a human anti-TNF-α mAb, we evaluated the formation of antibodies to adalimumab, efficacy and adverse events among 15 patients with highly active rheumatoid arthritis. Four patients were treated with adalimumab as monotherapy, and 11 patients with concomitant DMARDs. Disease activity was measured by DAS28. The antibodies were detected by ELISA. Thirteen (87%) patients withdrew from therapy within 45 weeks and overall 13 (87%) patients showed antibodies to adalimumab including 11 patients who withdrew from therapy. In four patients without concomitant DMARDs and in nine patients with concomitant DMARDs, we detected anti-adalimumab antibodies. Overall, five of seven patients with adverse drug reactions and all nine patients with lack of efficacy were associated with the formation of antibodies. Two antibody-positive patients developed an exantheme. The results indicate that adalimumab is, in spite of its fully human sequences, immunogenic and induces antibodies in a high rate of adalimumab-treated patients.

Keywords

Immunogenicity Anti-adalimumab antibodies Adverse events Clinical response 

References

  1. 1.
    van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H (2004) Efficacy an safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508–516PubMedCrossRefGoogle Scholar
  2. 2.
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45PubMedCrossRefGoogle Scholar
  3. 3.
    Food and Drug Administration. Adalimumab—for use in the treatment of rheumatoid arthritis. Abbott biologic licensing application. (Accessed April 26, 2004, at http://www.fda.gov/cder/biologics/review/adalabb123102r1.htm.)
  4. 4.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedGoogle Scholar
  5. 5.
    Ledingham J, Deighton C (2005) Update on the British Society for Rheumatology guidelines for prescribing TNF α blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 44:157–163PubMedCrossRefGoogle Scholar
  6. 6.
    den Broeder AA, Creemers MCW, van Gestel AM, van Riel PLCM (2002) Dose titration using the disease activity score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-α. Rheumatology 41:638–642CrossRefGoogle Scholar
  7. 7.
    Ritter G, Cohen LS, Williams C Jr, Richards EC, Old LJ, Welt S 2001 Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 61:6851–6859PubMedGoogle Scholar
  8. 8.
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259PubMedCrossRefGoogle Scholar
  9. 9.
    Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange MLM, McDonnell ND, Weinblatt ME (1999) Etanercept therapy in rheumatoid arthritis. A randomised, controlled trial. Ann Intern Med 130:478–486PubMedGoogle Scholar
  10. 10.
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiss MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586–1593PubMedCrossRefGoogle Scholar
  11. 11.
    Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342:763–769PubMedCrossRefGoogle Scholar
  12. 12.
    Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014–2022PubMedCrossRefGoogle Scholar
  13. 13.
    Baert F, Noman M, Vermeire S, Van Assche G, D’ Haens G, Carbonez A, Rutgeerts P (2003) Influence of Immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348:601–608PubMedCrossRefGoogle Scholar
  14. 14.
    Miele E, Markowitz J E, Mamula P, Baldassano RN (2004) Human Antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 38:502–508PubMedCrossRefGoogle Scholar
  15. 15.
    Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549PubMedCrossRefGoogle Scholar
  16. 16.
    Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P (2003) Autoimmunity associated with anti–tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study. Gastroenterology 125:32–39PubMedCrossRefGoogle Scholar
  17. 17.
    Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olsen A, Bao W, Hanauer SB (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126:402–413PubMedCrossRefGoogle Scholar
  18. 18.
    Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. The ATTRACT Study Group. Lancet 354:1932–1939PubMedCrossRefGoogle Scholar
  19. 19.
    Lipsky PE, van der Heijde DMFM, Clair EWT, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594–1602PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Niko K. Bender
    • 1
  • Christoph E. Heilig
    • 1
  • Benjamin Dröll
    • 2
  • Jessica Wohlgemuth
    • 2
  • Franz-Paul Armbruster
    • 2
  • Bernhard Heilig
    • 1
  1. 1.Rheumapraxis HeidelbergHeidelbergGermany
  2. 2.Immundiagnostik AGBensheimGermany

Personalised recommendations